Top Insights
GSK is taking over development of an avian influenza vaccine candidate as a bird flu outbreak continues in U.S. dairy cows. Meanwhile, CureVac is restructuring and returning its attention to cancer vaccines, which was the initial focus of the mRNA company.
The post GSK Pays CureVac €400M to Pick Up Clinical-Stage mRNA Vaccines for Infectious Diseases appeared first on MedCity News.
Recent Posts
Categories
Related Articles
Healthcare Moves: A Monthly Summary of Hires and Layoffs
Here is a selection of recent executive hires, exits, promotions and layoffs...
Medicaid Expansion is a Red and Blue State Issue
With President-elect Trump returning to the White House and Republicans controlling Congress,...
THCB Gang Episode 146, Tuesday November 26
Joining Matthew Holt (@boltyboy) on #THCBGang on Tuesday November 26 at 1PM...
Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition
Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for...
Leave a comment